Peptides in Alzheimer's Disease
* Please kindly note that our products and services can only be used to support research purposes (Not for clinical use).
- β-Amyloid (1-42), (1-40), (1-46) and Fragments
- Amyloid (APP) Precursor 770 Fragments
- β-Amyloid (HFIP-treated) and Salts (HCI,TFA)
- β-Amyloid Mutations
- Labeled Amyloid Peptides
- Modified Amyloids
- Modifiers of Aβ-Aggregation
- β-and γ-Secretase Inhibitors
- Tau Fragments
- Various Products/Alzheimer's Disease
Alzheimer's disease (AD) currently presents one of the biggest healthcare issues in the developed countries. It is a progressive neurodegenerative disease and causes a complex multi-factorial disorder among the elderly (typically after the age of 65 years). Although five drugs have been approved by the U.S. Food and Drug Administration (FDA) for the treatment, these drugs are not capable of slowing down disease progression but only are used to relieve symptoms.
The cause of Alzheimer's disease is poorly understood. About 70% of the risk is believed to be genetic with many genes usually involved. There are several different hypotheses trying to explain the cause of the disease, such as amyloid hypothesis, cholinergic hypothesis, tau hypothesis and mitochondrial cascade hypothesis etc. Among them amyloid hypothesis and Tau hypothesis have drawn much attention.
Aβ peptides are generated through the proteolytic cleavage of amyloid precursor protein (APP), a transmembrane protein, by enzyme complexes α, β and γ-secretases. In 1991, the amyloid hypothesis postulated that extracellular amyloid beta (Aβ) deposition is the basic cause of the Alzheimer disease. Specifically, this hypothesis suggests that the formation, aggregation, and deposition of Aβ peptides, and especially Aβ (1-42), is a fundamental process in AD pathogenesis which causes neurotoxicity and neurodegeneration. Based on the amyloid hypothesis, drugs that can reduce the generation of Aβ, prevent the aggregation of Aβ, and promote its clearance are thought to be promising therapeutics for AD.
Tau proteins are highly soluble and abundant in the neurons where they play a critical role in microtubule stabilization. In this hypothesis, hyperphosphorylated tau begins to pair with other threads of tau. Eventually, they form neurofibrillary tangles inside nerve cell bodies. When this occurs, the microtubules disintegrate, destroying the structure of the cell's cytoskeleton. This may eventually causes neurodegeneration and neuronaldeath. In recent years, immunomodulation was suggested as a viable option for promoting effective clearance of Tau aggregates.
The tau protein contains 85 potential serine (S), threonine (T), and tyrosine (Y) phosphorylation sites, and under normal conditions phosphorylation helps to maintain cytoskeletal structure. Abnormal phosphorylation of tau is known to contribute to AD pathology, with approximately 45 specific phosphorylation sites identified in the AD brain. Tau is subject to multiple post-translational modifications in addition to phosphorylation, including glycosylation, oxidation and aggregation etc. Today, there is a worldwide effort under way to find better ways to treat the disease, delay its onset, and prevent it from developing.
With long-standing experience of peptide synthesis, Creative Peptides can offer most comprehensive AD related peptides, from milligram to kilogram quantities at predefined purity levels even GMP grade peptides, for worldwide clients. Many experts working in Creative Peptides have actively pursued complicated peptide design and manufacturing for more than a decade. Consequently, our experts are skilled in complex peptide synthesis, even sophisticated peptide modifications such as glycosylation, DOTA, phosphorylation etc.
Please kindly check list below for the AD related peptides from Creative Peptides. If you have any custom peptide services requirement in mind, please contact us at email@example.com. We will be more than happy to serve you.